January 24, 2020 -- Evotec and Indivumed announced on January 23 a partnership to collaborate on drug discovery and development of novel therapies for non-small cell lung cancer. The goal of the collaboration is to provide highly effective precision medicine treatments for patients.
Evotec will bring its proprietary bioinformatics analysis platform called PanHunter to the table and also several small-molecule and antibody discovery platforms. Indivumed will provide access to its multiomics cancer database, IndivuType, along with advanced analytics and artificial intelligence capabilities. High-quality oncology patient data will complement advanced multiomics data analysis for the development of small-molecule and antibody therapies.
This agreement is a continuation of a previous joint drug discovery program focused on colorectal cancer started in April 2019.